Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing

Riccardo Masetti, Ilaria Castelli, A. Astolfi, Salvatore Nicola Bertuccio, Valentina Indio, Marco Togni, Tamara Belotti, S. Serravalle, Giuseppe Tarantino, Marco Zecca, M. Pigazzi, Giuseppe Basso, Andrea Pession, Franco Locatelli

Research output: Contribution to journalArticle

Abstract

Despite significant improvement in treatment of childhood acute myeloid leukemia (AML), 30% of patients experience disease recurrence, which is still the major cause of treatment failure and death in these patients. To investigate molecular mechanisms underlying relapse, we performed whole-exome sequencing of diagnosis-relapse pairs and matched remission samples from 4 pediatric AML patients without recurrent cytogenetic alterations. Candidate driver mutations were selected for targeted deep sequencing at high coverage, suitable to detect small subclones (0.12%). BiCEBPa mutation was found to be stable and highly penetrant, representing a separate biological and clinical entity, unlike WT1 mutations, which were extremely unstable. Among the mutational patterns underlying relapse, we detected the acquisition of proliferative advantage by signaling activation (PTPN11 and FLT3-TKD mutations) and the increased resistance to apoptosis (hyperactivation of TYK2). We also found a previously undescribed feature of AML, consisting of a hypermutator phenotype caused by SETD2 inactivation. The consequent accumulation of new mutations promotes the adaptability of the leukemia, contributing to clonal selection. We report a novel ASXL3 mutation characterizing a very small subclone (<1%) present at diagnosis and undergoing expansion (60%) at relapse. Taken together, these findings provide molecular clues for designing optimal therapeutic strategies, in terms of target selection, adequate schedule design and reliable response-monitoring techniques.

Original languageEnglish
Pages (from-to)56746-56757
Number of pages12
JournalOncotarget
Volume7
Issue number35
DOIs
Publication statusPublished - 2016

Fingerprint

Clonal Evolution
Exome
Acute Myeloid Leukemia
Recurrence
Mutation
High-Throughput Nucleotide Sequencing
Treatment Failure
Cytogenetics
Appointments and Schedules
Leukemia
Pediatrics
Apoptosis
Phenotype
Therapeutics

Keywords

  • Acute myeloid leukemia relapse
  • FLT3-TKD mutation
  • Pediatric acute myeloid leukemia
  • SETD2 mutation
  • Whole-exome massively parallel sequencing

ASJC Scopus subject areas

  • Oncology

Cite this

Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. / Masetti, Riccardo; Castelli, Ilaria; Astolfi, A.; Bertuccio, Salvatore Nicola; Indio, Valentina; Togni, Marco; Belotti, Tamara; Serravalle, S.; Tarantino, Giuseppe; Zecca, Marco; Pigazzi, M.; Basso, Giuseppe; Pession, Andrea; Locatelli, Franco.

In: Oncotarget, Vol. 7, No. 35, 2016, p. 56746-56757.

Research output: Contribution to journalArticle

Masetti, R, Castelli, I, Astolfi, A, Bertuccio, SN, Indio, V, Togni, M, Belotti, T, Serravalle, S, Tarantino, G, Zecca, M, Pigazzi, M, Basso, G, Pession, A & Locatelli, F 2016, 'Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing', Oncotarget, vol. 7, no. 35, pp. 56746-56757. https://doi.org/10.18632/oncotarget.10778
Masetti, Riccardo ; Castelli, Ilaria ; Astolfi, A. ; Bertuccio, Salvatore Nicola ; Indio, Valentina ; Togni, Marco ; Belotti, Tamara ; Serravalle, S. ; Tarantino, Giuseppe ; Zecca, Marco ; Pigazzi, M. ; Basso, Giuseppe ; Pession, Andrea ; Locatelli, Franco. / Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. In: Oncotarget. 2016 ; Vol. 7, No. 35. pp. 56746-56757.
@article{061fa84708bd4e81ab5fbb694adf94bf,
title = "Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing",
abstract = "Despite significant improvement in treatment of childhood acute myeloid leukemia (AML), 30{\%} of patients experience disease recurrence, which is still the major cause of treatment failure and death in these patients. To investigate molecular mechanisms underlying relapse, we performed whole-exome sequencing of diagnosis-relapse pairs and matched remission samples from 4 pediatric AML patients without recurrent cytogenetic alterations. Candidate driver mutations were selected for targeted deep sequencing at high coverage, suitable to detect small subclones (0.12{\%}). BiCEBPa mutation was found to be stable and highly penetrant, representing a separate biological and clinical entity, unlike WT1 mutations, which were extremely unstable. Among the mutational patterns underlying relapse, we detected the acquisition of proliferative advantage by signaling activation (PTPN11 and FLT3-TKD mutations) and the increased resistance to apoptosis (hyperactivation of TYK2). We also found a previously undescribed feature of AML, consisting of a hypermutator phenotype caused by SETD2 inactivation. The consequent accumulation of new mutations promotes the adaptability of the leukemia, contributing to clonal selection. We report a novel ASXL3 mutation characterizing a very small subclone (<1{\%}) present at diagnosis and undergoing expansion (60{\%}) at relapse. Taken together, these findings provide molecular clues for designing optimal therapeutic strategies, in terms of target selection, adequate schedule design and reliable response-monitoring techniques.",
keywords = "Acute myeloid leukemia relapse, FLT3-TKD mutation, Pediatric acute myeloid leukemia, SETD2 mutation, Whole-exome massively parallel sequencing",
author = "Riccardo Masetti and Ilaria Castelli and A. Astolfi and Bertuccio, {Salvatore Nicola} and Valentina Indio and Marco Togni and Tamara Belotti and S. Serravalle and Giuseppe Tarantino and Marco Zecca and M. Pigazzi and Giuseppe Basso and Andrea Pession and Franco Locatelli",
year = "2016",
doi = "10.18632/oncotarget.10778",
language = "English",
volume = "7",
pages = "56746--56757",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "35",

}

TY - JOUR

T1 - Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing

AU - Masetti, Riccardo

AU - Castelli, Ilaria

AU - Astolfi, A.

AU - Bertuccio, Salvatore Nicola

AU - Indio, Valentina

AU - Togni, Marco

AU - Belotti, Tamara

AU - Serravalle, S.

AU - Tarantino, Giuseppe

AU - Zecca, Marco

AU - Pigazzi, M.

AU - Basso, Giuseppe

AU - Pession, Andrea

AU - Locatelli, Franco

PY - 2016

Y1 - 2016

N2 - Despite significant improvement in treatment of childhood acute myeloid leukemia (AML), 30% of patients experience disease recurrence, which is still the major cause of treatment failure and death in these patients. To investigate molecular mechanisms underlying relapse, we performed whole-exome sequencing of diagnosis-relapse pairs and matched remission samples from 4 pediatric AML patients without recurrent cytogenetic alterations. Candidate driver mutations were selected for targeted deep sequencing at high coverage, suitable to detect small subclones (0.12%). BiCEBPa mutation was found to be stable and highly penetrant, representing a separate biological and clinical entity, unlike WT1 mutations, which were extremely unstable. Among the mutational patterns underlying relapse, we detected the acquisition of proliferative advantage by signaling activation (PTPN11 and FLT3-TKD mutations) and the increased resistance to apoptosis (hyperactivation of TYK2). We also found a previously undescribed feature of AML, consisting of a hypermutator phenotype caused by SETD2 inactivation. The consequent accumulation of new mutations promotes the adaptability of the leukemia, contributing to clonal selection. We report a novel ASXL3 mutation characterizing a very small subclone (<1%) present at diagnosis and undergoing expansion (60%) at relapse. Taken together, these findings provide molecular clues for designing optimal therapeutic strategies, in terms of target selection, adequate schedule design and reliable response-monitoring techniques.

AB - Despite significant improvement in treatment of childhood acute myeloid leukemia (AML), 30% of patients experience disease recurrence, which is still the major cause of treatment failure and death in these patients. To investigate molecular mechanisms underlying relapse, we performed whole-exome sequencing of diagnosis-relapse pairs and matched remission samples from 4 pediatric AML patients without recurrent cytogenetic alterations. Candidate driver mutations were selected for targeted deep sequencing at high coverage, suitable to detect small subclones (0.12%). BiCEBPa mutation was found to be stable and highly penetrant, representing a separate biological and clinical entity, unlike WT1 mutations, which were extremely unstable. Among the mutational patterns underlying relapse, we detected the acquisition of proliferative advantage by signaling activation (PTPN11 and FLT3-TKD mutations) and the increased resistance to apoptosis (hyperactivation of TYK2). We also found a previously undescribed feature of AML, consisting of a hypermutator phenotype caused by SETD2 inactivation. The consequent accumulation of new mutations promotes the adaptability of the leukemia, contributing to clonal selection. We report a novel ASXL3 mutation characterizing a very small subclone (<1%) present at diagnosis and undergoing expansion (60%) at relapse. Taken together, these findings provide molecular clues for designing optimal therapeutic strategies, in terms of target selection, adequate schedule design and reliable response-monitoring techniques.

KW - Acute myeloid leukemia relapse

KW - FLT3-TKD mutation

KW - Pediatric acute myeloid leukemia

KW - SETD2 mutation

KW - Whole-exome massively parallel sequencing

UR - http://www.scopus.com/inward/record.url?scp=84984870636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984870636&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10778

DO - 10.18632/oncotarget.10778

M3 - Article

VL - 7

SP - 56746

EP - 56757

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 35

ER -